Yakup Ergün, Medical Oncologist at Bower Hospital, shared on X:
”In a retrospective analysis of 606 patients with EGFR-mutant NSCLC receiving 1L osimertinib, both L858R and TP53 co-mutations were associated with worse outcomes, with the poorest outcomes observed in patients with L858R + TP53 co-mutations.
This may be considered when selecting combination strategies.”
Title: The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC)
Authors: Hye Sung Kim, Li Zhang, J. Nicholas Bodor, Margie L. Clapper, Hossein Borghaei, Martin J. Edelman, Yunyun Zhou, Mitchell Cheung, Joseph Treat
Other articles about Yakup Ergün on OncoDaily.